A5053238978- Herpesvirus Infections and Treatments
- Virus-based gene therapy research
- RNA Interference and Gene Delivery
- Poxvirus research and outbreaks
- interferon and immune responses
- Influenza Virus Research Studies
- Viral Infectious Diseases and Gene Expression in Insects
- Cytokine Signaling Pathways and Interactions
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Stress Responses and Cortisol
- Tryptophan and brain disorders
- Viral Infections and Outbreaks Research
- Cervical Cancer and HPV Research
- Neuroendocrine regulation and behavior
- Immune Response and Inflammation
- Monoclonal and Polyclonal Antibodies Research
- Bartonella species infections research
- Bacteriophages and microbial interactions
- Dermatology and Skin Diseases
- Atrial Fibrillation Management and Outcomes
- Animal Disease Management and Epidemiology
- HIV Research and Treatment
- Animal Virus Infections Studies
- Power Systems and Technologies
Orion Corporation (Finland)
2022-2025
University of Turku
2013-2023
ABT-263 and its structural analogues ABT-199 ABT-737 inhibit B-cell lymphoma 2 (Bcl-2), BCL2L1 long isoform (Bcl-xL) BCL2L2 (Bcl-w) proteins promote cancer cell death. Here, we show that at non-cytotoxic concentrations, these small molecules accelerate the deaths of non-cancerous cells infected with influenza A virus (IAV) or other viruses. In particular, demonstrate altered Bcl-xL interactions Bcl-2 antagonist death (Bad), Bcl-2-associated X protein (Bax), uveal autoantigen coiled-coil...
Viral diseases remain serious threats to public health because of the shortage effective means control. To combat surge viral diseases, new treatments are urgently needed. Here we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced premature death cells infected with different RNA or DNA viruses, whereas, at same concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited replication and spread....
The approval of the first oncolytic virus for treatment metastatic melanoma and compiling evidence that use viruses can enhance cancer immunotherapies targeted against various immune checkpoint proteins has attracted great interest in field virotherapy. We have developed a novel platform clinically relevant enveloped direct virus-induced response tumor antigens. By physically attaching tumor-specific peptides onto viral envelope vaccinia herpes simplex 1 (HSV-1), we were able to induce...
ABSTRACT Decorin (DCN) is a small extracellular proteoglycan with significant oncosuppressive activity. Lung adenocarcinoma commonly devoid of DCN expression and leading cause cancer mortality globally. As proof‐of‐concept study for evaluating the potential in lung cells, we constructed an oncolytic herpes simplex virus type 1 (HSV‐1) vector, transgene, using transfection‐infection method. Treatment cell line A549 this novel DCN‐expressing HSV‐1 vector led to significantly increased...
There is a growing demand for chimeric antigen receptor (CAR) -T cells clinical trials. Consequently, new centers capable of manufacturing advanced therapy medicinal products (ATMPs) are needed. In this study, we established good practice -compliant process and phase-appropriate analytics novel autologous CD19-targeted CAR T-cell product, 19-FiCART. We evaluated the stability fresh, healthy donor-derived leukapheresis (LPs), produced 19-FiCART using 12-day semi-automated with...
Abstract Background: The first-generation immune checkpoint inhibitors anti-PD1/PDL1 and anti-CTLA-4 either alone or in combination have shown tremendous clinical success BRAF wild type melanoma cancer patients. However, there is still a high unmet need as great proportion of patients relapsed after treatment with first generation mutant patient inhibitors. Chimeric antigen receptor (CAR) expressing T cells hematological malignancies, recent studies that CAR Ts were detected circulation...
RNA interference (RNAi)-based sequence-specific gene silencing is applied to identify function and also possesses great potential for inhibiting virus replication both in animals plants. Small interfering (siRNA) molecules are the inducers of RNAi pathway but may display immunostimulatory activities promote apoptosis. Canonical siRNAs 21 nucleotides (nt) length loaded Induced Silencing Complex when introduced into cells, while longer siRNA first processed by endogenous Dicer thus termed...
Herpes simplex virus type 1 (HSV-1) has properties that can be exploited for the development of gene therapy vectors. The neurotropism HSV enables delivery therapeutic genes to nervous system. Using a bacterial artificial chromosome (BAC), we constructed an HSV-1(17+)-based replicative vector deleted neurovirulence γ134.5, and expressing leukemia inhibitory factor (LIF) as transgene treatment experimental autoimmune encephalomyelitis (EAE). EAE is inducible T-cell mediated disease central...
Herpes simplex virus (HSV) is a common human pathogen. Despite current antivirals, it causes significant medical burden. Drug resistant strains exist and they are especially prevalent in immunocompromised patients HSV eye infections. New treatment modalities needed.BALB/c mice were corneally infected with subsequently treated swarm of enzymatically created, Dicer-substrate small interfering RNA (siRNA) molecules that targeted the gene UL29. Two infection models used, one which was...
A majority of adults in Finland are seropositive carriers herpes simplex viruses (HSV). Infection occurs at epithelial or mucosal surfaces, after which virions enter innervating nerve endings, eventually establishing lifelong infection neurons the sensory autonomic nervous system. Recent data have highlighted genetic diversity HSV-1 strains and demonstrated apparent geographic patterns strain similarity. Though multiple genomes been sequenced from Europe to date, there is a lack Nordic...
Herpes simplex virus (HSV) is a common human pathogen causing severe diseases such as encephalitis, keratitis, and neonatal herpes. There no vaccine against HSV the current antiviral chemotherapy fails to treat certain forms of disease. Here, we evaluated activity enzymatically created small interfering (si)RNA pools various pathogenic strains potential candidates for therapies. Pools siRNA targeting 0.5–0.8 kbp essential genes UL54 , UL29 or UL27 were synthesized. Efficacy inhibition each...
After a primary lytic infection at the epithelia, herpes simplex virus type 1 (HSV-1) enters innervating sensory neurons and translocates to nucleus, where it establishes quiescent latent infection. Periodically, can reactivate progeny viruses spread back epithelium. Here, we introduce an embryonic mouse dorsal root ganglion (DRG) culture system, which be used study mechanisms that control establishment, maintenance reactivation from latency. Use of acyclovir is not necessary in our model....
Herpes simplex virus (HSV) is a human pathogen that can cause severe diseases such as encephalitis, keratitis and neonatal herpes. Control of HSV infection may be achieved by using small interfering (si)RNAs. We have designed enzymatically produced pools siRNAs targeting HSV. In addition to the target-specific effects, induce innate immunity responses contribute antiviral effects. has versatile ways modulating immunity, it remains unclear whether HSV-specific treatment would benefit from...
Herpes simplex virus type 1 (HSV-1) is a common of mankind and HSV-1 infections are significant cause blindness. The current antiviral treatment herpes infection relies on acyclovir related compounds. However, resistance emerges especially in the long term prophylactic that required for prevention recurrent keratitis. Earlier we have established siRNA swarms, targeting sequences essential genes HSV, as effective means silencing replication HSV vitro or vivo . In this study, show efficacy...
Acyclovir is the drug of choice for treatment herpes simplex virus (HSV) infections. Acyclovir-resistant HSV strains may emerge, especially during long-term use, and subsequently cause difficult-to-treat exacerbations. Previously, we set up a novel approach, based on enzymatically synthesized pools siRNAs, or siRNA swarms. These swarms can cover kilobases-long target sequences, reducing likelihood resistance to treatment. Swarms targeting UL29 essential gene HSV-1 have demonstrated high...
Interleukin-27 (IL-27) inhibits the replication of many viruses, but mechanism differs according to virus and cell type. In this study, we observed that IL-27 expression was upregulated in herpes simplex type 1 (HSV-1)-infected SJL/J mice, which led us further investigate role HSV-1 infection using epithelial, glioma, immunological cells as models. We showed all studied lines, messenger RNA (mRNA) level due infection. When were primed with before infection, release prevented, indicating an...
Herpes simplex virus (HSV) has proven successful in treating human cancer. Since the approval of talimogene laherparepvec (T-VEC) 2015, HSV been thoroughly researched to discover novel mechanisms combat cancer and treat other diseases. Another HSV-based drug, beremagene geperpavec (B-VEC), received 2023 rare genetic disease dystrophic epidermolysis bullosa, was also first clinically approved vector carrying an extracellular matrix (ECM)-modifying transgene. The ECM is a network...
Herpes simplex virus (HSV) is a well-known, ubiquitous pathogen of humans. Engineered mutants HSV can also be exploited as vectors in gene therapy or for virotherapy tumors. has multiple abilities to evade and modulate the innate adaptive responses host. The increasing knowledge on mutual interactions invading with host defenses will contribute our deeper understanding relationship between host, thereby lead future development more effective specific treatment human diseases. advances...
Herpes simplex virus (HSV) establishes latency in neurons and recurrent infections oral mucosa. This prospective study analyzes HSV prevalence mucosal brush samples from men with known human papillomavirus (HPV) status. We hypothesized that HSV‐1‐infection could facilitate HPV persistence as a cofactor. was part of the Finnish Family accomplished at University Turku/Turku Hospital, Finland. A total 139 (mean age 28.6 ± 4.9 years) were enrolled 36+‐weeks their partner's pregnancy thereafter...